Osocimab, formerly known as BAY 1213790, represents a groundbreaking monoclonal protein currently experiencing clinical evaluation for the therapy of multiple hematologic cancers. This compound primarily targets CD38, https://rafaeldlre775931.blogdigy.com/osocimab-a-deep-examination-into-bay-1213790-and-its-promise-67210697